Life Science Investing Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences
Life Science Investing Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
Life Science Investing Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation
Life Science Investing Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market
Life Science Investing Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
